Neuroprotective potential of combination of resveratrol and 4-amino 1,8 naphthalimide in experimental diabetic neuropathy: Focus on functional, sensorimotor and biochemical changes

Free Radical Research

Volumn 43, Issue 4, 2009, Pages 400-408

  Sharma, Shyam S ^a   Kumar, Ashutosh ^a   Arora, Manish ^a   Kaundal, Ravinder K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetes; Reactive oxygen species (ROS); Resveratrol

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 4 AMINO 1,8 NAPHTHALIMIDE; MALONALDEHYDE; NAPHTHALIMIDE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXYNITRITE; RESVERATROL; UNCLASSIFIED DRUG; 1 NAPHTHYLAMINE; 4-AMINO-1,8-NAPHTHALIMIDE; ANTIOXIDANT; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; PEROXYNITROUS ACID; POLY(ADENOSINE DIPHOSPHATE RIBOSE); QUINOLONE DERIVATIVE; STILBENE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; ANIMAL; DRUG EFFECT; METABOLISM; NEURALGIA; OXIDATIVE STRESS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

1-NAPHTHYLAMINE; ANIMALS; ANTIOXIDANTS; DIABETIC NEUROPATHIES; MALE; MALONDIALDEHYDE; NAD; NAPHTHALIMIDES; NEURAL CONDUCTION; NEURALGIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PAIN MEASUREMENT; PEROXYNITROUS ACID; POLY ADENOSINE DIPHOSPHATE RIBOSE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; STILBENES;

EID: 67650180132     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760902801509     Document Type: Article

References (41)

1. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, pp. 1047-1053.
2. Vincent, AM, Edwards, JL, Sadidi, M. and Feldman, EL (2008) The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets, 9, pp. 94-100.
3. Vincent, AM, Russell, JW, Low, P. and Feldman, EL (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev, 25, pp. 612-628.
4. Obrosova, IG, Xu, W., Lyzogubov, VV, Ilnytska, O., Mashtalir, N., Vareniuk, I., Pavlov, IA, Zhang, J., Slusher, B. and Drel, VR (2008) PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med, 44, pp. 972-981.
5. Matsumoto, T., Ono, Y., Kuromiya, A., Toyosawa, K., Ueda, Y. and Bril, V. (2008) Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J Pharmacol Sci, 107, pp. 340-348.
6. Sugimoto, K., Yasujima, M. and Yagihashi, S. (2008) Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des, 14, pp. 953-961.
7. Yamagishi, S., Fukami, K., Ueda, S. and Okuda, S. (2007) Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets, 8, pp. 952-959.
8. Wolff, SP (1993) Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull, 49, pp. 642-652.
9. Evans, JL, Goldfine, ID, Maddux, BA and Grodsky, GM (2002) Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev, 23, pp. 599-622.
10. Yorek, MA, Coppey, LJ, Gellett, JS, Davidson, EP, Bing, X., Lund, DD and Dillon, JS (2002) Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. Am J Physiol Endocrinol Metab, 283, pp. E1067-E1075.
11. Arora, M., Kumar, A., Kaundal, RK and Sharma, SS (2008) Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimental diabetic neuropathy. Eur J Pharmacol, 596, pp. 77-83.
12. Kumar, A., Kaundal, RK, Iyer, S. and Sharma, SS (2007) Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci, 80, pp. 1236-1244.
13. Saini, AK, Kumar, HSA and Sharma, SS (2007) Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Eur J Pharmacol, 568, pp. 164-172.
14. Sayyed, SG, Kumar, A. and Sharma, SS (2006) Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci, 79, pp. 777-783.
15. Sharma, SS and Sayyed, SG (2006) Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clin Exp Pharmacol Physiol, 33, pp. 1022-1028.
16. Leiro, J., Arranz, JA, Fraiz, N., anmartin, ML, Quezada, E. and Orallo, F. (2005) Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol, 25, pp. 393-406.
17. Chen, CY, Jang, JH, Li, MH and Surh, YJ (2005) Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun, 331, pp. 993-1000.
18. Das, S. and Das, DK (2007) Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets, 6, pp. 168-173.
19. Hsieh, TC, Lu, X., Wang, Z. and Wu, JM (2006) Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Med Chem, 2, pp. 275-285.
20. Pham-Marcou, TA, Beloeil, H., Sun, X., Gentili, M., Yaici, D., Benoit, G., Benhamou, D. and Mazoit, JX (2008) Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: Prolonged effect related to COX-2 expression impairment. Pain, 140, pp. 274-283.
21. Zamin, LL, Dillenburg-Pilla, P., Argenta-Comiran, R., Horn, AP, Simao, F., Nassif, M., Gerhardt, D., Frozza, RL and Salbego, C. (2006) Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of PI3-K pathway. Neurobiol Dis, 21, p. 21.
22. Pacher, P., Liaudet, L., Soriano, FG, Mabley, JG, Szabo, E. and Szabo, C. (2002) The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes, 51, pp. 514-521.
23. Stevens, MJ, Li, F., Drel, VR, Abatan, OI, Kim, H., Burnett, D., Larkin, D. and Obrosova, IG (2007) Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther, 320, pp. 458-464.
24. Ilnytska, O., Lyzogubov, VV, Stevens, MJ, Drel, VR, Mashtalir, N., Pacher, P., Yorek, MA and Obrosova, IG (2006) Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes, 55, pp. 1686-1694.
25. Sharma, SS, Kumar, A. and Kaundal, RK (2008) Protective effects of 4-amino1,8-naphthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci, 82, pp. 570-576.
26. de Murcia, G. and Menissier de Murcia, J (1994) Poly(ADP-ribose) polymerase: A molecular nick-sensor. Trends Biochem Sci, 19, pp. 172-176.
27. Hassa, PO and Hottiger, MO (2002) The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci, 59, pp. 1534-1553.
28. Zheng, L., Szabo, C. and Kern, TS (2004) Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes, 53, pp. 2960-2967.
29. Banasik, M., Komura, H., Shimoyama, M. and Ueda, K. (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem, 267, pp. 1569-1575.
30. Kabra, DG, Thiyagarajan, M., Kaul, CL and Sharma, SS (2004) Neuroprotective effect of 4-amino-1,8-naphthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Res Bull, 62, pp. 425-433.
31. Obrosova, IG, Li, F., Abatan, OI, Forsell, MA, Komjati, K., Pacher, P., Szabo, C. and Stevens, MJ (2004) Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes, 53, pp. 711-720.
32. Sharma, SS and Sayyed, SG (2006) Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clin Exp Pharmacol Physiol, 33, pp. 1022-1028.
33. Ohkawa, H., Ohishi, N. and Yagi, K. (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 95, pp. 351-358.
34. Nisselbaum, JS and Green, S. (1969) A simple ultramicro method for determination of pyridine nucleotides in tissue. Anal Biochem, 27, pp. 212-217.
35. Virag, L. and Szabo, C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev, 54, pp. 375-429.
36. Cohen-Armon, M., Visochek, L., Rozensal, D., Kalal, A., Geistrikh, I., Klein, R., Bendetz-Nezer, S., Yao, Z. and Segar, R. (2007) DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: A link to histone acetylation. Molec Cell, 25, pp. 297-308.
37. Coppey, LJ, Gellett, JS, Davidson, EP, Dunlap, JA and Yorek, MA (2002) Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes Metab Res Rev, 18, pp. 49-56.
38. Soriano, FG, Virag, L. and Szabo, C. (2001) Diabetic endothelial dysfunction: Role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med, 79, pp. 437-448.
39. Calcutt, NA (2004) Modeling diabetic sensory neuropathy in rats. Methods Mol Med, 99, pp. 55-65.
40. Kameoka, M., Ota, K., Tetsuka, T., Tanaka, Y., Itaya, A., Okamoto, T. and Yoshihara, K. (2000) Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem J, 346, pp. 641-649.
41. Virag, L., Szabo, E., Gergely, P. and Szabo, C. (2003) Peroxynitrite-induced cytotoxicity: Mechanism and opportunities for intervention. Toxicol Lett, 140, pp. 113-124.